What is the fair value of PolyPid (NASDAQ-PYPD) stock?

The current fair value estimate for PolyPid (NASDAQ-PYPD) is $4.04. This implies an estimated downside of 4.4% versus the current market price.

Is PolyPid (NASDAQ-PYPD) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 4.4% versus the current market price.

What is the analyst price target for NASDAQ-PYPD stock?

The available analyst price target for PolyPid (NASDAQ-PYPD) is $12.25. The analyst target implies estimated upside of 189.6%.

How is the financial health of PolyPid?

The current financial health read for PolyPid (NASDAQ-PYPD) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is PolyPid's next earnings date?

The next earnings date currently listed for PolyPid (NASDAQ-PYPD) is August 12, 2026.

Does PolyPid (NASDAQ-PYPD) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for PolyPid (NASDAQ-PYPD)?

The current P/E ratio listed for PolyPid (NASDAQ-PYPD) is -2.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of PolyPid?

The current market capitalization listed for PolyPid is 98.747 M.

What is the enterprise value of PolyPid?

The current enterprise value listed for PolyPid is 90.181 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for PolyPid?

The ticker symbol for PolyPid is NASDAQ-PYPD, and the stock is listed on NASDAQ.

Where is PolyPid (NASDAQ-PYPD) listed?

PolyPid (NASDAQ-PYPD) is listed on NASDAQ.

What is the debt-to-total-capital ratio for PolyPid?

The current debt-to-total-capital ratio listed for PolyPid is 2.3%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for PolyPid?

The free float listed for PolyPid is 56.9%. Free float helps investors understand how much of the share base is available for public trading.

PolyPid (PYPD) Fair Value & Stock Analysis

PolyPid (PYPD)

PolyPid Ltd. is a biopharmaceutical company listed on the NASDAQ under the ticker PYPD. The company is developing targeted, locally administered, prolonged-release therapeutics based on its proprietary PLEX technology, which is designed to address unmet medical needs. Its lead candidate, D-PLEX100, is being evaluated in a pivotal Phase 3 confirmatory trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery involving large incisions. PolyPid is also advancing OncoPLEX, a preclinical program focused on intra-tumoral cancer treatment. In addition, the company has a research and development collaboration with ImmunoGenesis, Inc. aimed at developing formulations for solid tumors. PolyPid was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-PYPD	$4.04	-4.4% Downside	Fair	$12.25	189.6% Upside	Bargain	Fair	—	—	—	0.0%	August 12, 2026	-2.9x	11.2x	—	98.747 M	90.181 M	2.3%	56.9%	-58.2	—	83.5%